Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.
Stocks · News reference
BlossomHill Therapeutics Q2 EPS $(8.75)
BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
8-K filing — BlossomHill Therapeutics, Inc. (BLSM)
Filed: 2026-09-18 AccNo: 0001193125-26-395031 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Earnings Scheduled For September 18, 2026
Companies Reporting Before The Bell • BlossomHill Therapeutics (NASDAQ:BLSM) is expected to report earnings for its second quarter. Companies Reporting After The Bell This article was generated by Benzinga's